Boehringer Ingelheim Canada and the University Hospital Foundation (UHF) established the Alberta Boehringer Ingelheim Interstitial Lung Disease (ABILD), a new partnership with a focus on progressive fibrosing interstitial lung disease (ILD). ILDs comprise more than 200 respiratory diseases known to cause breathing difficulties. About 18% to 32% of…
News
Patients diagnosed with idiopathic pulmonary fibrosis (IPF) in more recent years appear to have a lower risk of mortality on a short-term basis than those diagnosed more than 10 years ago, a study has found. According to the researchers, these differences in short-term mortality may be due to changes…
The Centers for Medicare and Medicaid Services (CMS) has given the status of Advanced Diagnostic Laboratory Test (ADLT) to the Envisia Genomic Classifier, Veracyte’s genomic test specifically designed to facilitate the diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The…
Action for Pulmonary Fibrosis (APF) and the U.K. Royal College of General Practitioners (RCGP) have created and launched a training module to help doctors provide better care for patients with pulmonary fibrosis (PF). The training will cover the signs and symptoms of PF, as well as where to…
The amount of bilirubin in the blood might predict the progression of idiopathic pulmonary fibrosis (IPF), according to a recent study. If validated in larger studies, bilirubin levels in the blood — or serum bilirubin — could offer a cheaper, simpler, and more convenient blood test than other…
From lighting landmarks in blue to showcasing patient stories, supporters are finding ways to mark Pulmonary Fibrosis Awareness Month, set aside each September to call attention to the lung condition and raise funds to fight it. The monthlong campaign is spearheaded each year by the Pulmonary Fibrosis Foundation…
A new 3D model of lung tissue allowed the scientists who developed it to identify aspects of pulmonary fibrosis (PF) not evident in the 2D models often used in research. This new model, developed by a research team at the University of Michigan, revealed potentially important aspects of fibrosis and…
Using Cymerus mesenchymal stem cells (MSCs) to treat idiopathic pulmonary fibrosis (IPF) resulted in dramatic reductions in IPF symptoms and significant improvements in lung functionality in an animal model of the disease, Cynata Therapeutics, the company developing this stem cell therapy, reported. These…
In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness about the realities of this disease and how it affects people’s lives. The PFF is also conducting a social media campaign, “30 Facts in 30 Days,” to educate the public…
Procalcitonin, a precursor of the calcitonin hormone, may be used as a potential biomarker of lung cancer developing in people with idiopathic pulmonary fibrosis (IPF), a recent study suggests. Compared with patients with IPF alone, procalcitonin was significantly higher in IPF patients who also had lung…
